Combining and Sequencing Sipuleucel-T in CRPC

Phase 2 Co-PSMA data showed higher lesion detection with 64Cu-SAR-bisPSMA vs 68Ga-PSMA-11 in biochemical recurrence after prostatectomy.

Thomas Powles, MBBS, MRCP, MD, discusses LITESPARK-022 QOL findings and patient selection for adjuvant belzutifan plus pembrolizumab in RCC.

Experts weigh genomic testing, treatment intensification, and radioligand sequencing in advanced prostate cancer care.

The PCR-based OncoMate MSI Dx Analysis System can now identify patients with MSI-H solid tumors who may be eligible for pembrolizumab.

The FDA set a June 25, 2027, target action date for gedatolisib plus fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.

A dual antigen–targeted T-cell engager doublet produced durable PSA responses in late-line metastatic castration-resistant prostate cancer.

VET3-TGI produced responses in injected and non-injected lesions without dose-limiting toxicities in the phase 1/1b STEALTH-001 trial.

IL-1β blockade with canakinumab was well tolerated and reduced nodule size in patients with high-risk indeterminate pulmonary nodules.